Pfizer and Strides Arcolab agrees new licensing deal

Pfizer has agreed a new licensing and supply deal with Strides Arcolab which will allow it to enhance its oncology treatment offering in Europe and other regions.

Under the terms of the agreement, Pfizer is to add up to 38 generic cancer treatments from Strides to its portfolio, to be sold via its Established Products business unit.

It represents an extension of the collaboration agreed by the two companies in January 2010, with a separate deal having also been finalised relating to niche sterile injectables for the US market.

In total, 45 products are now covered by the Pfizer/Strides partnership, with the first of the new treatments set to be commercialised in late 2010 or early 2011.

David Simmons, president and general manager of Pfizer’s Established Products division, said: “We are excited about extending our important partnership with Strides to reach an even larger global patient population.”

Last week, Pfizer announced that it has acquired the commercial rights to terguride, a new treatment for pulmonary arterial hypertension which is currently being developed by Ergonex.